US Congress to investigate Ranbaxy approvals
This article was originally published in Scrip
Executive Summary
The US Congress is jumping into the fray over allegations of possible fraud involving Ranbaxy's generic drug applications. Democratic leaders of the House energy and commerce committee said they will investigate the firm's drug approvals and potential violations of good manufacturing practice regulations, as well as the FDA's knowledge of any misconduct.